Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-tetrahydropyridine toxicity

Journal of Neurochemistry

Volumn 93, Issue 2, 2005, Pages 493-501

  Conti, Bruno ^a   Sugama, Shuei ^b   Lucero, Jacinta ^a   Winsky Sommerer, Raphaelle ^a   Wirz, Sebastian A ^a   Maher, Pamela ^a   Andrews, Zane ^c   Barr, Alasdair M ^a   Morale, Maria C ^a,d   Paneda, Covadonga ^a   Pemberton, Janell ^a   Gaidarova, Svetlana ^a   Behrens, M Margarita ^a   Beal, Flint ^e   Sanna, Pietro Paolo ^a   Horvath, Tamas L ^c   Bartfai, Tamas ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c YALE UNIVERSITY   (United States)

^d OASI RESEARCH INSTITUTE IRCCS   (Italy)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

MPTP; Parkinson; Uncoupling protein 2

Indexed keywords

1,2,3,6 METHYLPHENYLTETRAHYDROPYRIDINE; PYRIDINE DERIVATIVE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE NERVE CELL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; LOCOMOTION; MALE; MITOCHONDRION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DOPAMINE; ION CHANNELS; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, TRANSGENIC; MITOCHONDRIAL PROTEINS; NEURONS; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 20244377700     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03052.x     Document Type: Article

References (53)

1. Beal M. F., Matthews R., T., Tieleman A. and Shults C. W. (1998) Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 783, 109-114.
2. Bechmann I., Diano S., Warden C. H., Bartfai T., Nitsch R. and Horvath T. L. (2002) Brain mitochondrial uncoupling protein 2 (UCP2): a protective stress signal in neuronal injury. Biochem. Pharmacol. 64, 363-367.
3. Bouillaud F., Couplan E., Pecqueur C. and Ricquier D. (2001) Homologues of the uncoupling protein from brown adipose tissue (UCP1) Ucp2, Ucp3, Bmcp1 Ucp4. Biochim. Biophys. Acta 1504, 107-119.
4. Breidert T., Callebert J., Heneka M. T., Landreth G., Latinay J. M. and Hirsch E. C. (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82, 615-624.
5. Clavel S., Paradis E., Ricquier D. and Richard D. (2003) Kainic acid upregulates uncoupling protein-2 mRNA expression in the mouse brain. Neuroreport. 14, 2015-2017.
6. Coggeshall R. E. (1992) A consideration of neural counting methods. Trends Neurosci. 15, 9-13.
7. DeGiorgio L. A., Dibinis C., Milner T. A., Saji M. and Volpe B. T. (1998) Histological and temporal characteristics of nigral transneuronal degeneration after striatal injury. Brain Res. 795, 1-9.
8. Di Monte D. A. (2003) The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2, 531-538.
9. Diano S., Matthews R., Patrylo P., Yang L., Beal M., Bamstable C. and Horvath T. (2003) Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology. 144, 5014-5021.
10. Echtay K. S., Wiakler E. and Klingenberg M. (2000) Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature. 408, 609-613.
11. Echtay K. S., Murphy M. P., Smith R. A., Talbot D. A. and Brand M. D. (2002) Superoxide activates mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted antioxidants. J. Biol. Chem. 277, 47 129-47 135.
12. Fleury C., Neverova M., Collins S. et al. (1997) Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 15, 269-272.
13. Greenamyre J. T., Sherer T. B., Betarbet R. and Panov A. V. (2001) Complex I and Parkinson's disease. IUBMB Life 52, 135-141.
14. Gundersen H. J. (1992) Stereology: the fast lane between neuroanatomy and brain function - or still only a tightrope? Acta Neurol. Scand. Suppl. 137, 8-13.
15. Halliwell B. and Gutteridge J. M. (1985) The importance of free radicals and catalytic metal ions in human diseases. Mol. Aspects Med. 8, 89-193.
16. Horvath K. M., Radnai B., Bela T. E., Fekete M. I. and Nagy G. M. (1999a) Inhibition of protein phosphatase 2A (PP2A) mimics suckling-induced sensitization of mammotropes: involvement of a pertussis toxin (PTX) sensitive G-protein and the adenylate cyclase (AC). Mol. Cell Endocrinol. 149, 1-7.
17. Horvath T. L., Warden C. H., Hajos M., Lombardi A., Goglia F. and Diano S. (1999b) Brain uncoupling protein 2: uncoupled neuronal mitochondria predict thermal synapses in homeostatic centers. J. Neurosci. 19, 10 417-10 427.
18. Horvath T. L., Diano S., Leranth C. et al. (2003) Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology. 144, 27 57-27 60.
19. Jenner P. and Olanow C. W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47, S161-S170.
20. Kaur D., Yantiri F., Rajagopalan S. et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 37, 899-909.
21. Keller J. N., Kindy M. S., Holtsberg F. W., St Clair D. K., Yen H. C., Germeyer A., Steiner S. M., Bruce-Keller A. J., Hutchins J. B. and Mattson M. P. (1998) Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci. 18, 687-697.
22. Kim-Han J. S., Reichert S. A., Quick K. L. and Dugan L. L. (2001) BMCP1: a mitochondrial uncoupling protein in neurons which regulates mitochondrial function and oxidant production, J. Neurochem. 79, 658-668.
23. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392, 605-608.
24. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 18, 106-108.
25. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A. and Czlonkowska A. (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156, 50-61.
26. Lotharius J. and O'Malley K. L. (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275, 38 581-38 588.
27. Lowell B. B. and Spiegelman B. M. (2000) Towards a molecular understanding of adaptive thermogenesis. Nature. 404, 652-660.
28. Mao W., YuX. X., Zhong A., Li W., Brush J., Sherwood S. W., Adams S. H. and Pan G. (1999) UCP4, a novel brain-specific mitochondrial protein that reduces membrane potential in mammalian cells. FEBS Lett. 443, 326-330 [Erratum FEBS Lett. 449, 293].
29. Matthews R. T., Ferrante R. J., Klivenyi P., Yang L., Klein A. M., Mueller G., Kaddurah-Daouk R. and Beal M. F. (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157, 142-149.
30. Mattiasson G., Shamloo M., Gido G. et al. (2003) Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat. Med. 9, 1062-1068.
31. Min N., Joh T. H., Corp E. S., Baker H., Cubells J. F. and Son J. H. (1996) A transgenic mouse model to study transsynaptic regulation of tyrosine hydroxylase gene expression. J. Neurochem. 67, 11-18.
32. Nakamura K., Bindokas V. P., Marks J. D., Wright D. A., Frim D. M., Miller R. J. and Kang U. J. (2000) The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol. Pharmacol. 58, 271-278.
33. Nishikawa T., Du Edelstein D. X. L., Yamagishi S. et al. (2000) Normalizing mitochondrial Superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404, 787-790.
34. Olanow C. W. (1990) Oxidation reactions in Parkinson's disease. Neurology. 40, 37-39.
35. Olanow C. W. (1993) A radical hypothesis for neurodegeneration. Trends Neurosci. 16, 439-444.
36. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276, 2045-2047.
37. Przedborski S., Tieu K., Perier C. and Vila M. (2004) MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembr. 36, 375-379.
38. Richard D., Rivest R., Huang Q., Bouillaud F., Sanchis D., Champigny O. and Ricquier D. (1998) Distribution of the uncoupling protein 2 mRNA in the mouse brain. J. Comp. Neurol. 397, 549-560.
39. Rojas P. and Rios C. (1993) Increased striatal lipid peroxidation after intracerebroventricular MPP+ administration to mice. Pharmacol. Toxicol. 72, 364-368.
40. Saji M., Blau A. D. and Volpe B. T. (1996) Prevention of transneuronal degeneration of neurons in the substantia nigra reticulata by ablation of the subthalamic nucleus. Exp. Neurol. 141, 120-129.
41. Sanchis D., Fleury C., Chomiki N. et al. (1998) BMCP1, a novel mitochondrial carrier with high expression in the central nervous system of humans and rodents, and respiration uncoupling activity in recombinant yeast. J. Biol. Chem. 273, 34 611-34 615.
42. Sedelis M., Schwarring R. K. and Huston J. P. (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125, 109-125.
43. Sherer T. B., Betarbet R., Testa C. M., Seo B. B., Richardson J. R., Kim J. H., Miller G. W., Yagi T., Matsuno-Yagi A. and Greenamyre J. T. (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23, 10 756-10 764.
44. Shimokawa T., Kato M., Watanabe Y., Hirayama R., Kurosaki E., Shikama H. and Hashimoto S. (1998) In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice. Biochem. Biophys. Res. Commun. 251, 374-378.
45. Sugama S., Cho B. P., Baker H., Joh T. H., Lucero J. and Conti B. (2002) Neurons of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat CNS. Brain Res. 958, 1-9.
46. Sugama S., Yang L., Cho B. P., DeGiorgio L. A., Lorenzl S., Albers D. S., Beal M. F., Volpe B. T. and Joh T. H. (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res. 964, 288-294.
47. Sullivan P. G., Dube C., Dorenbos K., Steward O. and Baram T. Z. (2003) Mitochondrial uncoupling protein-2 protects the immature brain from excitotoxic neuronal death. Ann. Neurol. 53, 711-717.
48. Tan S., Sagara Y., Liu Y., Maher P. and Schubert D. (1998) The regulation of reactive oxygen species production during programmed cell death. J. Cell Biol. 141, 1423-1432.
49. Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.
50. Vidal-Puig A. J. (2000) Uncoupling expectations. Nat. Genet. 26, 387-388.
51. Vidal-Puig A. J., Grujic D., Zhang C. Y. et al. (2000) Energy metabolism in uncoupling protein 3 gene knockout mice. J. Biol. Chem. 275, 16 258-16 266.
52. Volpe B. T., Wildmann J. and Altar C. A. (1998) Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience. 83, 741-748.
53. Zou L., Xu J., Jankovic J., He Y., Appel S. H. and Le W. (2000) Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine C57BL/6 mice. Neurosci. Lett. 281, 167-170.